Hims & Hers Health

Mounting Regulatory Costs And Intensifying Telehealth Competition Will Undermine Prospects

AnalystLowTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

04 May 25

Updated

16 Aug 25

AnalystLowTarget's Fair Value

US$28.00

61.1% overvalued

16 Aug

US$45.10

172.3%

-9.8%

Author's Valuation

US$28.0

61.1% overvalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on08 May 25
Fair value Increased 12%

AnalystLowTarget Fair Value

US$28.0

61.1% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.68%

Healthcare Services revenue growth rate

0.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$271.63m

Earnings '28

32.00x

PE Ratio '28

US$8.69b

Market Cap '28

US$8.69b

Market Cap '28

255.11m

No. shares '28

US$34.07

Share Price '28

US$34.07 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$27.99

Fair Value '25

Mounting Regulatory Costs And Intensifying Telehealth Competition Will Undermine Prospects

Shared on08 May 25Fair value Increased 12%

Shared on08 May 25
Fair value Increased 12%